Mirae Asset Global Investments’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Mirae Asset Global Investments’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-81,452	Closed	-$342K	–	2757
2023 Q1	$342K	Buy	81,452 +43,056	+112%	+$223K	﹤0.01%	2101
2022 Q4	$231K	Hold	38,396	–	–	﹤0.01%	2255
2022 Q3	$223K	Buy	38,396 +11,900	+45%	+$74.2K	﹤0.01%	2297
2022 Q2	$158K	Buy	+26,496	New	+$136K	﹤0.01%	2214

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Mirae Asset Global Investments's CTIC Position: Q2 2023 in Review

Mirae Asset Global Investments sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 81,452 shares — an estimated $342K sold.

Mirae Asset Global Investments first reported a position in CTIC in Q2 2022 and held it in 4 quarters. The position peaked at $342K in Q1 2023. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Mirae Asset Global Investments reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Mirae Asset Global Investments sold 81,452 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $342K.
Mirae Asset Global Investments first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2022 and held it in 4 quarters.
Mirae Asset Global Investments's CTI BioPharma Corp. (DE) Common Stock position peaked at $342K in Q1 2023.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Mirae Asset Global Investments's 13F filing for Q2 2023, filed 10 Aug 2023.